These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25229463)

  • 1. With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs?
    Peltekian KM
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):417-8. PubMed ID: 25229463
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiviral therapy of chronic hepatitis C: 30 years success story].
    Abdurakhmanov DT; Rozina TP; Nikulkina EN; Burnevich EZ; Tanashuk EL; Severov MV; Filatova AL; Milovanova SY; Karpov VV; Moiseev SV
    Ter Arkh; 2019 Nov; 91(11):110-115. PubMed ID: 32598621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The importance of using ribavirin in treating chronic hepatitis C].
    Xie Y; Li MH
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):930-1. PubMed ID: 17196140
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
    Feld JJ
    Gastroenterology; 2012 May; 142(6):1356-9. PubMed ID: 22537443
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy.
    Hu SL; Jaber BL
    Clin Nephrol; 2005 Jan; 63(1):41-5. PubMed ID: 15678695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C genotype 3: a tough match for interferon-free regimens.
    Aghemo A; Colombo M
    Gastroenterology; 2014 Apr; 146(4):1125-7. PubMed ID: 24566101
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ribavirin: a new drug in the treatment of chronic hepatitis C].
    Salmerón J
    Gastroenterol Hepatol; 1997; 20(7):363-5. PubMed ID: 9377236
    [No Abstract]   [Full Text] [Related]  

  • 9. Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
    Patel K; Dev A; Muir AJ; McHutchison JG
    Hepatology; 2003 Jul; 38(1):21-4. PubMed ID: 12829982
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?
    Rou WS; Lee BS
    Clin Mol Hepatol; 2015 Jun; 21(2):122-4. PubMed ID: 26157748
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon-free treatment regimens for hepatitis C: are we there yet?
    Sharma P; Lok AS
    Gastroenterology; 2011 Dec; 141(6):1963-7. PubMed ID: 22033188
    [No Abstract]   [Full Text] [Related]  

  • 12. Effective antiviral treatment for hepatitis C virus-related chronic active hepatitis in haemophiliac patients.
    Capra F; De Maria E; Franchini M; Gandini G
    Dig Liver Dis; 2001 May; 33(4):389. PubMed ID: 11432520
    [No Abstract]   [Full Text] [Related]  

  • 13. [Peginterferon alpha combined with ribavirin for the treatment of chronic hepatitis C].
    Xu Y; Wang JB
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jun; 19(6):415-6. PubMed ID: 22053369
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment for hepatitis C virus associated cryoglobulinemia with interferon alpha and ribavirin].
    Altuna L; Fernández J; Castiella A
    Rev Esp Enferm Dig; 2005 Jul; 97(7):531-2. PubMed ID: 16262533
    [No Abstract]   [Full Text] [Related]  

  • 15. Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
    Jung YK; Kim JH
    Clin Mol Hepatol; 2013 Mar; 19(1):26-8. PubMed ID: 23593606
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
    Chung WJ
    Clin Mol Hepatol; 2012 Sep; 18(3):268-71. PubMed ID: 23091806
    [No Abstract]   [Full Text] [Related]  

  • 17. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
    Coton T; Diallo I
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e95. PubMed ID: 23663919
    [No Abstract]   [Full Text] [Related]  

  • 19. Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Wahid B; Saleem K; Ali A; Rafique S; Idrees M
    Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):979-980. PubMed ID: 28471832
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs.
    Higgs P; Wright C; Hellard M
    Aliment Pharmacol Ther; 2016 Apr; 43(7):840-1. PubMed ID: 26932412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.